SGLT2 inhibition and heart failure—current concepts

Joaquim Silva Custodio, Andre Rodrigues Duraes, Marconi Abreu, Natalia Albuquerque Rocha, Leonardo Roever

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Type 2 diabetes mellitus (T2DM) is a major risk factor for several cardiovascular (CV) conditions, including heart failure (HF). However, until recently, no therapy to treat patients with diabetes could also reduce CV risks related to HF. The EMPA-REG OUTCOME trial with empagliflozin was the first to demonstrate significant cardioprotective benefits in this population. Its impressive 35% reduction in hospitalizations for HF drew the attention of the scientific community to the possibility that pharmacologic sodium-glucose cotransporter 2 (SGLT2) inhibition could be part of the armamentarium for treating patients with HF, with and without diabetes. The recently published CANVAS Program (with canagliflozin) and real-life data from the CVD-Real Study (using dapagliflozin, empagliflozin, and canagliflozin) further strengthened this hypothesis, suggesting that the observed benefit is not restricted to a particular drug, but is rather a class effect. This review explores the effects of pharmacologic SGLT2 inhibitors’ use in cardiac function and discusses the potential role of this class of medication as a treatment for HF.

Original languageEnglish (US)
Pages (from-to)409-418
Number of pages10
JournalHeart Failure Reviews
Volume23
Issue number3
DOIs
StatePublished - May 1 2018

Fingerprint

Sodium-Glucose Transport Proteins
Heart Failure
Treatment Failure
Type 2 Diabetes Mellitus
Hospitalization
Pharmaceutical Preparations
Population

Keywords

  • Cardiovascular outcomes
  • Diabetes mellitus
  • Heart failure
  • SGLT2 inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Custodio, J. S., Duraes, A. R., Abreu, M., Albuquerque Rocha, N., & Roever, L. (2018). SGLT2 inhibition and heart failure—current concepts. Heart Failure Reviews, 23(3), 409-418. https://doi.org/10.1007/s10741-018-9703-2

SGLT2 inhibition and heart failure—current concepts. / Custodio, Joaquim Silva; Duraes, Andre Rodrigues; Abreu, Marconi; Albuquerque Rocha, Natalia; Roever, Leonardo.

In: Heart Failure Reviews, Vol. 23, No. 3, 01.05.2018, p. 409-418.

Research output: Contribution to journalReview article

Custodio, JS, Duraes, AR, Abreu, M, Albuquerque Rocha, N & Roever, L 2018, 'SGLT2 inhibition and heart failure—current concepts', Heart Failure Reviews, vol. 23, no. 3, pp. 409-418. https://doi.org/10.1007/s10741-018-9703-2
Custodio JS, Duraes AR, Abreu M, Albuquerque Rocha N, Roever L. SGLT2 inhibition and heart failure—current concepts. Heart Failure Reviews. 2018 May 1;23(3):409-418. https://doi.org/10.1007/s10741-018-9703-2
Custodio, Joaquim Silva ; Duraes, Andre Rodrigues ; Abreu, Marconi ; Albuquerque Rocha, Natalia ; Roever, Leonardo. / SGLT2 inhibition and heart failure—current concepts. In: Heart Failure Reviews. 2018 ; Vol. 23, No. 3. pp. 409-418.
@article{e98b0ba5a919422c806baeefc86fc29d,
title = "SGLT2 inhibition and heart failure—current concepts",
abstract = "Type 2 diabetes mellitus (T2DM) is a major risk factor for several cardiovascular (CV) conditions, including heart failure (HF). However, until recently, no therapy to treat patients with diabetes could also reduce CV risks related to HF. The EMPA-REG OUTCOME trial with empagliflozin was the first to demonstrate significant cardioprotective benefits in this population. Its impressive 35{\%} reduction in hospitalizations for HF drew the attention of the scientific community to the possibility that pharmacologic sodium-glucose cotransporter 2 (SGLT2) inhibition could be part of the armamentarium for treating patients with HF, with and without diabetes. The recently published CANVAS Program (with canagliflozin) and real-life data from the CVD-Real Study (using dapagliflozin, empagliflozin, and canagliflozin) further strengthened this hypothesis, suggesting that the observed benefit is not restricted to a particular drug, but is rather a class effect. This review explores the effects of pharmacologic SGLT2 inhibitors’ use in cardiac function and discusses the potential role of this class of medication as a treatment for HF.",
keywords = "Cardiovascular outcomes, Diabetes mellitus, Heart failure, SGLT2 inhibitors",
author = "Custodio, {Joaquim Silva} and Duraes, {Andre Rodrigues} and Marconi Abreu and {Albuquerque Rocha}, Natalia and Leonardo Roever",
year = "2018",
month = "5",
day = "1",
doi = "10.1007/s10741-018-9703-2",
language = "English (US)",
volume = "23",
pages = "409--418",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - SGLT2 inhibition and heart failure—current concepts

AU - Custodio, Joaquim Silva

AU - Duraes, Andre Rodrigues

AU - Abreu, Marconi

AU - Albuquerque Rocha, Natalia

AU - Roever, Leonardo

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Type 2 diabetes mellitus (T2DM) is a major risk factor for several cardiovascular (CV) conditions, including heart failure (HF). However, until recently, no therapy to treat patients with diabetes could also reduce CV risks related to HF. The EMPA-REG OUTCOME trial with empagliflozin was the first to demonstrate significant cardioprotective benefits in this population. Its impressive 35% reduction in hospitalizations for HF drew the attention of the scientific community to the possibility that pharmacologic sodium-glucose cotransporter 2 (SGLT2) inhibition could be part of the armamentarium for treating patients with HF, with and without diabetes. The recently published CANVAS Program (with canagliflozin) and real-life data from the CVD-Real Study (using dapagliflozin, empagliflozin, and canagliflozin) further strengthened this hypothesis, suggesting that the observed benefit is not restricted to a particular drug, but is rather a class effect. This review explores the effects of pharmacologic SGLT2 inhibitors’ use in cardiac function and discusses the potential role of this class of medication as a treatment for HF.

AB - Type 2 diabetes mellitus (T2DM) is a major risk factor for several cardiovascular (CV) conditions, including heart failure (HF). However, until recently, no therapy to treat patients with diabetes could also reduce CV risks related to HF. The EMPA-REG OUTCOME trial with empagliflozin was the first to demonstrate significant cardioprotective benefits in this population. Its impressive 35% reduction in hospitalizations for HF drew the attention of the scientific community to the possibility that pharmacologic sodium-glucose cotransporter 2 (SGLT2) inhibition could be part of the armamentarium for treating patients with HF, with and without diabetes. The recently published CANVAS Program (with canagliflozin) and real-life data from the CVD-Real Study (using dapagliflozin, empagliflozin, and canagliflozin) further strengthened this hypothesis, suggesting that the observed benefit is not restricted to a particular drug, but is rather a class effect. This review explores the effects of pharmacologic SGLT2 inhibitors’ use in cardiac function and discusses the potential role of this class of medication as a treatment for HF.

KW - Cardiovascular outcomes

KW - Diabetes mellitus

KW - Heart failure

KW - SGLT2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85046015697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046015697&partnerID=8YFLogxK

U2 - 10.1007/s10741-018-9703-2

DO - 10.1007/s10741-018-9703-2

M3 - Review article

VL - 23

SP - 409

EP - 418

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 3

ER -